Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports.

Xalkori (crizotinib) - Pfizer

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42732396

Dunya Yang; Juan Yao; Lingdan Chen; Naying Yu; Qunxiang Chen; Shuyi Chen; Xi Chen; Xianglan Lin; Xiangwu Lin; Xiaoyu Zhang; Yun Yan

Sep 14, 2026